Abstract
Purpose
The purpose of this study is to synthesize and evaluate specific agents for molecular imaging of butyrylcholinesterase (BuChE), known to be associated with neuritic plaques and neurofibrillary tangles in Alzheimer’s disease (AD). In this study, these agents were tested in a normal rat model. The distribution of radiolabel was compared with known BuChE histochemical distribution in the rat brain.
Procedures
Iodobenzoate esters were synthesized and tested, through spectrophotometric analysis, as specific substrates for BuChE. These compounds were converted to the corresponding 123I esters from tributyltin intermediates and purified for studies in the rat model. Whole body dynamic scintigraphic images were obtained for biodistribution studies. Autoradiograms of brain sections were obtained and compared to histochemical distribution of the enzyme in this model system.
Results
The three iodobenzoate esters studied were specific substrates for BuChE. Whole body biodistribution studies with 123I-labeled compounds showed rapid disappearance from the body while radioactivity was retained in the head region. Brain section autoradiography of animals injected with these labeled compounds indicated that most areas known to contain BuChE corresponded to areas of radioactivity accumulation.
Conclusion
BuChE-specific radiolabeled iodobenzoates enter the brain and, in general, label areas known to exhibit BuChE activity in histochemical studies. Such molecules may represent a new direction for the development of agents for the molecular imaging of BuChE in the living brain, especially in regions where BuChE-containing neuropathological structures appear in AD.
Similar content being viewed by others
References
Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368:387–403
Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the national institute on aging and the reagan institute working group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56:1095–1097
Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2:1403
Bartus RT, Dean RL 3rd, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–414
Coyle JT, Price DL, DeLong MR (1983) Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 219:1184–1190
Perry EK, Perry RH, Blessed G, Tomlinson BE (1978) Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 4:273–277
Mesulam M-M, Geula C (1991) Acetylcholinesterase-rich neurons of the human cerebral cortex: cytoarchitectonic and ontogenetic patterns of distribution. J Comp Neurol 306:193–220
Friede RL (1967) A comparative histochemical mapping of the distribution of butyryl cholinesterase in the brains of four species of mammals, including man. Acta Anat 66:161–177 (Basel)
Darvesh S, Grantham DL, Hopkins DA (1998) Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. J Comp Neurol 393:374–390
Darvesh S, Hopkins DA (2003) Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol 463:25–43
Darvesh S, Hopkins DA, Geula C (2003) Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 4:131–138
Friede RL (1965) Enzyme histochemical studies of senile plaques. J Neuropathol Exp Neurol 24:477–491
Geula C, Mesulam M-M (1989) Special properties of cholinesterases in the cerebral cortex of Alzheimer’s disease. Brain Res 498:185–189
Mesulam M-M, Geula C (1994) Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 36:722–727
Geula C, Mesulam M-M (1995) Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord 9(Suppl 2):23–28
Guillozet AL, Smiley JF, Mash DC, Mesulam M-M (1997) Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 42:909–918
Darvesh S, Reid GA, Martin E (2010) Biochemical and histochemical comparison of cholinesterases in normal and alzheimer brain tissues. Curr Alzheimer Res 7:386–400
Snyder SE, Gunupudi N, Sherman PS et al (2001) Radiolabeled cholinesterase substrates: in vitro methods for determining structure-activity relationships and identification of a positron emission tomography radiopharmaceutical for in vivo measurement of butyrylcholinesterase activity. J Cereb Blood Flow Metab 21:132–143
Kikuchi T, Fukushi K, Ikota N, Ueda T, Nagatsuka S, Arano Y, Irie T (2001) Synthesis of piperidinyl and pyrrolidinyl butyrates for potential In Vivo measurement of cerebral butyrylcholinesterase activity. J Labelled Cpds Radiopharm 44:31–41
Kikuchi T, Zhang MR, Ikota N, Fukushi K, Okamura T, Suzuki K, Arano Y, Irie T (2004) N-[18 F]fluoroethylpiperidin-4-ylmethyl butyrate: a novel radiotracer for quantifying brain butyrylcholinesterase activity by positron emission tomography. Bioorg Med Chem Lett 14:1927–1930
Roivainen A, Rinne J, Virta J, Järvenpää T, Salomäki S, Yu M, Någren K (2004) Biodistribution and blood metabolism of 1–11 C-methyl-4-piperidinyl n-butyrate in humans: an imaging agent for in vivo assessment of butyrylcholinesterase activity with PET. J Nucl Med 45:2032–2039
Virta JR, Tolvanen T, Nagren K, Bruck A, Roivainen A, Rinne JO (2008) 1–11 C-methyl-4-piperidinyl-N-butyrate radiation dosimetry in humans by dynamic organ-specific evaluation. J Nucl Med 49:347–353
Kuhl DE, Koeppe RA, Snyder SE, Minoshima S, Frey KA, Kilbourn MR (2006) In vivo butyrylcholinesterase activity is not increased in Alzheimer’s disease synapses. Ann Neurol 59:13–20
Tago H, Maeda T, McGeer PL, Kimura H (1992) Butyrylcholinesterase-rich neurons in rat brain demonstrated by a sensitive histochemical method. J Comp Neurol 325:301–312
Darvesh S, Smereczynsky A, Hopkins DA (1992) Distribution of butyrylcholinesterase in the rat brain. Neurosci Abstr 18:1505 (Abstract)
Singh S, Basmadjian GP, Avor KS, Pouw B, Seale TW (1997) Synthesis and ligand binding studies of 4′-iodobenzoyl esters of tropanes and piperidines at the dopamine transporter. J Med Chem 40:2474–2481
Darvesh S, Kumar R, Roberts S, Walsh R, Martin E (2001) Butyrylcholinesterase-mediated enhancement of the enzymatic activity of trypsin. Cell Mol Neurobiol 21:285–296
Irvine CA (2006) Spartan ’06 Wave function Inc
Tetko IV, Tanchuk VY, Villa AE (2001) Prediction of n-octanol/water partition coefficients from PHYSPROP database using artificial neural networks and E-state indices. J Chem Inf Comput Sci 41:1407–1421
Darvesh S, Walsh R, Kumar R, Caines A, Roberts S, Magee D, Rockwood K, Martin E (2003) Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzheimer Dis Assoc Disord 17:117–126
Cheng CY, Brochmann-Hanssen E, Waters JA (1982) Quantitative structure-activity relationships of aromatic esters of 1-methyl-4-piperidinol as analgesics. J Med Chem 25:145–152
Waters JA, Hollingsworth EB, Daly JW, Lewandowski G, Creveling CR (1986) Anticonvulsant activity of piperidinol and (dialkylamino)alkanol esters. J Med Chem 29:1512–1516
Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, Nachon F (2003) Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 278:41141–41147
Sussman JL, Harel M, Silman I (1993) Three-dimensional structure of acetylcholinesterase and of its complexes with anticholinesterase drugs. Chem Biol Interact 87:187–197
Saxena A, Redman AM, Jiang X, Lockridge O, Doctor BP (1997) Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry 36:14642–14651
Silver A (1974) The biology of cholinesterases. Elsevier, Amsterdam
Kikuchi T, Okamura T, Fukushi K, Takahashi K, Toyohara J, Okada M, Zhang MR, Irie T (2007) Cerebral acetylcholinesterase imaging: development of the radioprobes. Curr Top Med Chem 7:1790–1799
Vaucher E, Borredon J, Seylaz J, Lacombe P (1995) Autoradiographic distribution of cerebral blood flow increases elicited by stimulation of the nucleus basalis magnocellularis in the unanesthetized rat. Brain Res 691:57–68
Acknowledgments
The Canadian Institutes of Health Research (MOP-82798), Canadian Institutes of Health Research Vascular Health and Dementia Initiative (DOV-78344) (through partnership of Canadian Institutes of Health Research, Heart & Stroke Foundation of Canada, the Alzheimer Society of Canada and Pfizer Canada Inc.), Capital District Health Authority Research Fund, Nova Scotia Health Research Foundation, National Sciences and Engineering Research Council, Canadian Foundation for Innovation, Dalhousie Radiology Research Foundation, Dalhousie University, and Mount Saint Vincent University are gratefully acknowledged. We thank Amy Morris, Marlene Hudgins, Melissa Morash, Anita Macdonald, Simone LaForest, and Eva Rogerson for their technical assistance.
Conflict of Interest Disclosure
Application for patent protection has been filed relating to the iodobenzoate esters described in this manuscript, through Treventis Corporation, in which one of the authors (SD) is a shareholder. SD made an invited presentation (possible mechanisms underlying effects of BuChE—emerging hypotheses to spark future research) at a mini-symposium entitled “Emerging hypotheses in cholinesterase inhibition: targeted activity for optimal effects”, organized by Novartis in Geneva as part of the 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. No funding has been received from either of these companies in support of the work described herein.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Macdonald, I.R., Reid, G.A., Joy, E.E. et al. Synthesis and Preliminary Evaluation of Piperidinyl and Pyrrolidinyl Iodobenzoates as Imaging Agents for Butyrylcholinesterase. Mol Imaging Biol 13, 1250–1261 (2011). https://doi.org/10.1007/s11307-010-0448-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-010-0448-0